<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIFABUTIN- rifabutin capsule </strong><br>Lupin Pharmaceuticals, Inc.<br></p></div>
<h1>Rifabutin Capsules USP, 150 mg<br><br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="ID2"></a>Rifabutin Capsules USP for oral administration contain 150 mg of the rifamycin antimycobacterial agent rifabutin, USP, per capsule, along with the inactive ingredients crospovidone, gelatin, iron oxide red, magnesium stearate, microcrystalline cellulose, potassium hydroxide, shellac, silicon dioxide, sodium lauryl sulphate, and titanium dioxide.</p>
<p>The chemical name for rifabutin is 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxorifamycin XIV (Chemical Abstracts Service, 9th Collective Index) or (9<span class="Italics">S</span>, 12<span class="Italics">E</span>, 14<span class="Italics">S</span>, 15<span class="Italics">R</span>, 16<span class="Italics">S</span>, 17<span class="Italics">R</span>, 18<span class="Italics">R</span>, 19<span class="Italics">R</span>, 20<span class="Italics">S</span>, 21<span class="Italics">S</span>, 22<span class="Italics">E</span>, 24<span class="Italics">Z</span>)-6,16,18,20-tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-spiro [9,4-(epoxypentadeca[1,11,13]trienimino)-2<span class="Italics">H-</span>furo[2',3':7,8] naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26-(3<span class="Italics">H</span>,9<span class="Italics">H</span>)-trione-16-acetate. Rifabutin has a molecular formula of C<span class="Sub">46</span>H<span class="Sub">62</span>N<span class="Sub">4</span>O<span class="Sub">11</span>, a molecular weight of 847.02 and the following structure:</p>
<div class="Figure">
<img alt="Rifabutin USP" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4be9cc3f-0016-4426-a700-574b45ce245b&amp;name=rifabutincaps-figure-01.jpg"><p class="MultiMediaCaption">Rifabutin USP</p>
</div>
<p><a name="ID4"></a>Rifabutin is a red-violet powder soluble in chloroform and methanol, sparingly soluble in ethanol, and very slightly soluble in water (0.19 mg/mL). Its log P value (the base 10 logarithm of the partition coefficient between n-octanol and water) is 3.2 (n-octanol/water).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID5"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="ID6"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><a name="ID7"></a><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Following a single oral dose of 300 mg to nine healthy adult volunteers, rifabutin was readily absorbed from the gastrointestinal tract with mean (±SD) peak plasma levels (C<span class="Sub">max</span>) of 375 (±267) ng/mL (range: 141 to 1033 ng/mL) attained in 3.3 (±0.9) hours (T<span class="Sub">max</span> range: 2 to 4 hours). Absolute bioavailability assessed in five HIV-positive patients, who received both oral and intravenous doses, averaged 20%. Total recovery of radioactivity in the urine indicates that at least 53% of the orally administered rifabutin dose is absorbed from the gastrointestinal tract. The bioavailability of rifabutin from the capsule dosage form, relative to an oral solution, was 85% in 12 healthy adult volunteers. High-fat meals slow the rate without influencing the extent of absorption from the capsule dosage form. Plasma concentrations post-C<span class="Sub">max</span> declined in an apparent biphasic manner. Pharmacokinetic dose-proportionality was established over the 300 mg to 600 mg dose range in nine healthy adult volunteers (crossover design) and in 16 early symptomatic human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV)-positive patients over a 300 mg to 900 mg dose range. </p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Due to its high lipophilicity, rifabutin demonstrates a high propensity for distribution and intracellular tissue uptake. Following intravenous dosing, estimates of apparent steady-state distribution volume (9.3 ± □1.5 L/kg) in five HIV-positive patients exceeded total body water by approximately 15-fold. Substantially higher intracellular tissue levels than those seen in plasma have been observed in both rat and man. The lung-to-plasma concentration ratio, obtained at 12 hours, was approximately 6.5 in four surgical patients who received an oral dose. Mean rifabutin steady-state trough levels (C<span class="Sub">p, min</span><span class="Sup">ss</span>; 24-hour post-dose) ranged from 50 to 65 ng/mL in HIV-positive patients and in healthy adult volunteers. About 85% of the drug is bound in a concentration-independent manner to plasma proteins over a concentration range of 0.05 to 1 mcg/mL. Binding does not appear to be influenced by renal or hepatic dysfunction. Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (± 17) hours (range: 16 to 69 hours). Although the systemic levels of rifabutin following multiple dosing decreased by 38%, its terminal half-life remained unchanged.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Of the five metabolites that have been identified, 25-O-desacetyl and 31-hydroxy are the most predominant, and show a plasma metabolite:parent area under the curve ratio of 0.10 and 0.07, respectively. The former has an activity equal to the parent drug and contributes up to 10% to the total antimicrobial activity.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>-balance study in three healthy adult volunteers with <span class="Sup">14</span>C-labeled rifabutin showed that 53% of the oral dose was excreted in the urine, primarily as metabolites. About 30% of the dose is excreted in the feces. Mean systemic clearance (CL<span class="Sub">s</span>/F) in healthy adult volunteers following a single oral dose was 0.69 (± 0.32) L/hr/kg (range: 0.46 to 1.34 L/hr/kg). Renal and biliary clearance of unchanged drug each contribute approximately 5% to CL<span class="Sub">s</span>/F.</p>
</div>
<div class="Section">
<a name="ID8"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics in Special Populations</h2>
<p class="First"><a name="ID9"></a><span class="Bold"><span class="Italics">Geriatric</span></span></p>
<p>Compared to healthy volunteers, steady-state kinetics of rifabutin are more variable in elderly patients (&gt;70 years).</p>
<p><span class="Bold"><span class="Italics">Pediatric</span></span></p>
<p>The pharmacokinetics of rifabutin have not been studied in subjects under 18 years of age.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The disposition of rifabutin (300 mg) was studied in 18 patients with varying degrees of renal function. Area under plasma concentration time curve (AUC) increased by about 71% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance below 30 mL/min) compared to patients with creatinine clearance (Cr<span class="Sub">cl</span>) between 61 to 74 mL/min. In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cr<span class="Sub">cl</span> between 30 to 61 mL/min), the AUC increased by about 41%. In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, carefully monitor for rifabutin associated adverse events. A reduction in the dosage of rifabutin is recommended for patients with Cr<span class="Sub">cl</span> &lt;30 mL/min if toxicity is suspected <span class="Italics">(see <a href="#ID62">DOSAGE AND ADMINISTRATION</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID10"></a><a name="section-2.3"></a><p></p>
<p class="First"><a name="ID11"></a><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not known. </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span> in HIV-Infected Patients</span></span></p>
<p>Alterations in gastric pH due to progressing <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> has been linked with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of some drugs used in HIV-positive patients (e.g., rifampin, isoniazid). Drug serum concentrations data from AIDS patients with varying disease severity (basedon CD4+ counts) suggests that rifabutin absorption is not influenced by progressing <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. </p>
<p><span class="Bold">Drug-Drug Interactions </span><span class="Italics">(see also <a href="#ID33">PRECAUTIONS</a>-<a href="#ID38">Drug Interactions</a>)</span> </p>
<p>Multiple dosing of rifabutin has been associated with induction of hepatic metabolic enzymes of the CYP3A subfamily. Rifabutin's predominant metabolite (25-desacetyl rifabutin: LM565), may also contribute to this effect. Metabolic induction due to rifabutin is likely to produce a decrease in plasma concentrations of concomitantly administered drugs that are primarily metabolized by the CYP3A enzymes. Similarly concomitant medications that competitively inhibit the CYP3A activity may increase plasma concentrations of rifabutin. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID12"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"><a name="ID13"></a>Two randomized, double-blind clinical trials (Study 023 and Study 027) compared rifabutin (300 mg/day) to placebo in patients with CDC-defined AIDS and CD4 counts ≤200 cells/µL. These studies accrued patients from 2/90 through 2/92. Study 023 enrolled 590 patients, with a median CD4 cell count at study entry of 42 cells/µL (mean 61). Study 027 enrolled 556 patients with a median CD4 cell count at study entry of 40 cells/µL (mean 58).</p>
<p>Endpoints included the following:</p>
<p>(1) MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, defined as at least one blood culture positive for <span class="Italics">Mycobacterium avium </span>complex (MAC) bacteria.</p>
<p>(2) Clinically significant disseminated MAC disease, defined as MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> accompanied by signs or symptoms of serious MAC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including one or more of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, worsening <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and/or elevations in alkaline phosphatase.</p>
<p>(3) Survival</p>
<div class="Section">
<a name="ID14"></a><a name="section-3.1"></a><p></p>
<h2>MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>
</h2>
<p class="First"><a name="ID15"></a>Participants who received rifabutin were one-third to one-half as likely to develop MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> as were participants who received placebo. These results were statistically significant (Study 023: p&lt;0.001; Study 027: p = 0.002).</p>
<p>In Study 023, the one-year cumulative incidence of MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, on an intent to treat basis, was 9% for patients randomized to rifabutin and 22% for patients randomized to placebo. In Study 027, these rates were 13% and 28% for patients receiving rifabutin and placebo, respectively.</p>
<p>Most cases of MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> (approximately 90% in these studies) occurred among participants whose CD4 count at study entry was ≤100 cells/µL. The median and mean CD4 counts at onset of MAC <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> were 13 cells/µL and 24 cells/µL, respectively. These studies did not investigate the optimal time to begin MAC prophylaxis.</p>
</div>
<div class="Section">
<a name="ID16"></a><a name="section-3.2"></a><p></p>
<h2>Clinically Significant Disseminated MAC Disease
</h2>
<p class="First"><a name="ID17"></a>In association with the decreased incidence of <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, patients on rifabutin showed reductions in the signs and symptoms of disseminated MAC disease, including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and hepatic dysfunction.</p>
</div>
<div class="Section">
<a name="ID18"></a><a name="section-3.3"></a><p></p>
<h2>Survival</h2>
<p class="First"><a name="ID19"></a>The one-year survival rates in Study 023 were 77% for the group receiving rifabutin and 77% for the placebo group. In Study 027, the one-year survival rates were 77% for the group receiving rifabutin and 70% for the placebo group. </p>
<p>These differences were not statistically significant.</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="ID20"></a><a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID21"></a><a name="section-4.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First"><a name="ID22"></a>Rifabutin inhibits DNA-dependent RNA polymerase in susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli </span>and <span class="Italics">Bacillus subtilis </span>but not in mammalian cells. In resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">E. coli</span>, rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits DNA-dependent RNA polymerase in <span class="Italics">Mycobacterium avium </span>or in <span class="Italics">M. intracellulare </span>which comprise <span class="Italics">M. avium </span>complex (MAC).</p>
</div>
<div class="Section">
<a name="ID23"></a><a name="section-4.2"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First"><a name="ID24"></a><span class="Italics">In vitro</span> susceptibility testing methods and diagnostic products used for determining <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) values against <span class="Italics">M. avium </span>complex (MAC) organisms have not been standardized. Breakpoints to determine whether clinical isolates of MAC and other mycobacterial species are susceptible or resistant to rifabutin have not been established.</p>
<p><span class="Bold"><span class="Italics">In Vitro</span> Studies</span></p>
<p>Rifabutin has demonstrated <span class="Italics">in vitro</span> activity against <span class="Italics">M. avium </span>complex (MAC) organisms isolated from both HIV-positive and HIV-negative people. While-gene probe techniques may be used to identify these two organisms; many reported studies did not distinguish between these two species. The vast majority of isolates from MAC-infected, HIV-positive people are <span class="Italics">M. avium</span>, whereas in HIV-negative people, about 40% of the MAC isolates are <span class="Italics">M. intracellulare</span>.</p>
<p>Various <span class="Italics">in vitro</span> methodologies employing broth or solid media, with and without polysorbate 80 (Tween 80), have been used to determine rifabutin MIC values for mycobacterial species. In general, MIC values determined in broth are several fold lower than that observed with methods employing solid media. Utilization of Tween 80 in these assays has been shown to further lower MIC values.</p>
<p>However, MIC values were substantially higher for egg-based compared to agar-based solid media. </p>
<p>Rifabutin activity against 211 MAC isolates from HIV-positive people was evaluated <span class="Italics">in vitro</span> utilizing a radiometric broth and an agar dilution method. Results showed that 78% and 82% of these isolates had MIC<span class="Sub">99</span> values of ≤0.25 mcg/mL and ≤1.0 mcg/mL, respectively, when evaluated by these two methods. Rifabutin was also shown to be active against phagocytized, <span class="Italics">M. avium </span>complex in a mouse macrophage cell culture model.</p>
<p>Rifabutin has <span class="Italics">in vitro</span> activity against many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>. In one study, utilizing the radiometric broth method, each of 17 and 20 rifampin-naive clinical isolates tested from the United States and Taiwan, respectively, were shown to be susceptible to rifabutin concentrations of ≤0.125 mcg/mL.</p>
<p>Cross-resistance between rifampin and rifabutin is commonly observed with <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and M. avium </span>complex isolates. Isolates of <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </span>resistant to rifampin are likely to be resistant to rifabutin. Rifampicin and rifabutin MIC<span class="Sub">99</span> values against 523 isolates of <span class="Italics">M. avium </span>complex were determined utilizing the agar dilution method (Heifets, Leonid B. and Iseman, Michael D. Determination of <span class="Italics">in vitro</span> susceptibility of Mycobacteria to Ansamycin. Am. Rev. Respir. Dis. 1985; 132(3):710-711).</p>
<a name="ID25"></a><table width="99%">
<col width="28%">
<col width="14%">
<col width="15%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="6" valign="top">
<span class="Bold">Table </span><span class="Bold">1</span><span class="Bold">: </span><span class="Bold">Susceptibility </span><span class="Bold">of </span><span class="Bold Italics">M</span><span class="Bold Italics">. </span><span class="Bold Italics">Avium </span><span class="Bold">Complex </span><span class="Bold">Strains </span><span class="Bold">to </span><span class="Bold">Rifampin </span><span class="Bold">and </span><span class="Bold">Rifabutin</span><span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" colspan="2" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top">
<span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Strains </span><span class="Bold">Susceptible</span><span class="Bold">/</span><span class="Bold">Resistant </span><span class="Bold">to </span><span class="Bold">Different </span><span class="Bold">Concentrations </span><span class="Bold">of </span><span class="Bold">Rifabutin </span><span class="Bold">(</span><span class="Bold">mcg</span><span class="Bold">/</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">
<span class="Bold">Susceptibility </span><span class="Bold">to </span><span class="Bold"><br></span><span class="Bold">Rifampin </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mcg</span><span class="Bold">/</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Number </span><span class="Bold">of </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Susceptible </span><span class="Bold">to </span><span class="Bold">0</span><span class="Bold">.</span><span class="Bold">5</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Resistant </span><span class="Bold">to </span><span class="Bold">0</span><span class="Bold">.</span><span class="Bold">5 </span><span class="Bold">only</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Resistant </span><span class="Bold">to </span><span class="Bold">1</span><span class="Bold">.</span><span class="Bold">0</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Resistant </span><span class="Bold">to </span><span class="Bold">2</span><span class="Bold">.</span><span class="Bold">0</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Susceptible to 1.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">100.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.0<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Resistant to 1.0 only<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">163<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">88.3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11.7<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.0<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Resistant to 5.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">105<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">38.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">57.1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.0<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Resistant to 10.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">225<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50.2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19.6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10.2<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">TOTAL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">523<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">49.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">36.7<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.8<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID69"></a>Rifabutin <span class="Italics">in vitro</span> MIC<span class="Sub">99</span> values of ≤0.5 mcg/mL, determined by the agar dilution method, for <span class="Italics">M. kansasii, M. gordonae </span>and <span class="Italics">M. marinum </span>have been reported; however, the clinical significance of these results is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID27"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="ID28"></a>Rifabutin capsules USP are indicated for the prevention of disseminated <span class="Italics">Mycobacterium avium </span>complex (MAC) disease in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID29"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="ID30"></a>Rifabutin capsules are contraindicated in patients who have had clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rifabutin or to any other rifamycins.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID31"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="ID32"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> </span></p>
<p>Rifabutin capsules must not be administered for MAC prophylaxis to patients with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Patients who develop complaints consistent with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> while on prophylaxis with rifabutin should be evaluated immediately, so that those with active disease may be given an effective combination regimen of anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> medications. Administration of rifabutin as a single agent to patients with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is likely to lead to the development of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> that is resistant both to rifabutin and to rifampin. </p>
<p>There is no evidence that rifabutin is an effective prophylaxis against <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>. Patients requiring prophylaxis against both <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </span>and <span class="Italics">Mycobacterium avium </span>complex may be given isoniazid and rifabutin concurrently. </p>
<p><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> in HIV-positive patients is common and may present with atypical or extrapulmonary findings. Patients are likely to have a nonreactive purified protein derivative (PPD) despite active disease. In addition to chest X-ray and <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> culture, the following studies may be useful in the diagnosis of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in the HIV-positive patient: blood culture, urine culture, or biopsy of a suspicious lymph node. </p>
<p><span class="Bold">MAC Treatment With Clarithromycin </span></p>
<p>When rifabutin is used concomitantly with clarithromycin for MAC treatment, a decreased dose of rifabutin is recommended due to the increase in plasma concentrations of rifabutin <span class="Italics">(see <a href="#ID33">PRECAUTIONS</a>-<a href="#ID38">Drug Interactions</a>, <a href="#ID70">Table 2</a>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and Related Reactions </span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may occur in patients receiving rifamycins. Signs and symptoms of these reactions may include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or flu-like syndrome (<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, sweats, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>). There have been reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> with the use of rifamycins. </p>
<p>Monitor patients receiving rifabutin therapy for signs and/or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. If these symptoms occur, administer supportive measures and discontinue rifabutin.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> </span></p>
<p>Due to the possible occurrence of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, patients should also be carefully monitored when rifabutin is given in combination with clarithromycin (or other macrolides) and/or fluconazole and related compounds <span class="Italics">(see <a href="#ID33">PRECAUTIONS</a>-<a href="#ID38">Drug Interactions</a>, <a href="#ID70">Table 2</a>).</span> If <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> is suspected, the patient should be referred to an ophthalmologist and, if considered necessary, treatment with rifabutin should be suspended <span class="Italics">(see also <a href="#ID50">ADVERSE REACTIONS</a>).</span> </p>
<p><span class="Bold"><span class="Italics">Clostridium difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </span></p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including rifabutin capsules, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated. </p>
<p><span class="Bold">Protease Inhibitor Drug Interaction </span></p>
<p>Protease inhibitors act as substrates or inhibitors of CYP3A4 mediated metabolism.  Therefore, due to significant drug-drug interactions between protease inhibitors and rifabutin, their concomitant use should be based on the overall assessment of the patient and a patient-specific drug profile. The concomitant use of protease inhibitors may require at least a 50% reduction in rifabutin dose, and depending on the protease inhibitor, an adjustment of the antiviral drug dose. Increased monitoring for adverse events is recommended when using these drug combinations <span class="Italics">(see <a href="#ID33">PRECAUTIONS</a>-<a href="#ID38">Drug Interactions</a>).</span> For further recommendations, please refer to current, official product monographs of the protease inhibitor or contact the specific manufacturer. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID33"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="ID34"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="ID35"></a>Because treatment with rifabutin capsules may be associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and more rarely <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, physicians should consider obtaining hematologic studies periodically in patients receiving prophylaxis with rifabutin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID36"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><a name="ID37"></a>Patients should be advised of the signs and symptoms of both MAC and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, and should be instructed to consult their physicians if they develop new complaints consistent with either of these diseases. In addition, since rifabutin may rarely be associated with <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> and <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, patients should be advised to notify their physicians if they develop signs or symptoms suggesting either of these disorders.</p>
<p>Urine, feces, saliva, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, perspiration, tears, and skin may be colored brown-orange with rifabutin and some of its metabolites. Soft contact lenses may be permanently stained. Patients to be treated with rifabutin should be made aware of these possibilities.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID38"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="ID39"></a><span class="Bold"><span class="Italics">Effect of Rifabutin on the Pharmacokinetics of Other Drugs</span></span> </p>
<p>Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir.</p>
<p><span class="Bold"><span class="Italics">Effect of Other Drugs on Rifabutin Pharmacokinetics</span></span> </p>
<p>Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is coadministered with CYP3A inhibitors. </p>
<p>Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity of the disease, patient's drug profile, and the likely impact on the risk/benefit ratio. </p>
<a name="ID70"></a><table width="99%">
<caption><span>Table 2: Rifabutin Interaction Studies</span></caption>
<col width="16%">
<col width="16%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="15%">
<col width="22%">
<tfoot>
<tr class="First"><td align="left" colspan="7"><p class="First Footnote">↑ indicates increase; ↓ indicates decrease; ↔ indicates no significant change <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote">QD-once daily; BID-twice daily; TID – thrice daily <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote">ND -No Data <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote">AUC -Area under the Concentration vs. Time Curve; C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> -Maximum serum concentration <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">a</span><span class="Sup"></span>compared to rifabutin 300 mg QD alone <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">b</span><span class="Sup"></span>compared to historical control (fosamprenavir/ritonavir 700/100 mg BID) <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">c</span><span class="Sup"></span>also taking zidovudine 500 mg QD<br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">d</span><span class="Sup"></span>compared to rifabutin 150 mg QD alone <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">e</span><span class="Sup"></span>compared to rifabutin 300 mg QD alone <br></p></td></tr>
<tr><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">f</span><span class="Sup"></span>data from a case report <br></p></td></tr>
<tr class="Last"><td align="left" colspan="7"><p class="First Footnote"><span class="Sup">g</span><span class="Sup"></span>compared to voriconazole 200 mg BID alone <br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Coadministered </span><span class="Bold">drug </span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Dosing </span><span class="Bold">regimen </span><span class="Bold">of </span><span class="Bold">coadministered </span><span class="Bold">drug</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Dosing </span><span class="Bold">regimen </span><span class="Bold">of </span><span class="Bold">rifabutin</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Study </span><span class="Bold">population </span><span class="Bold">(</span><span class="Bold">n</span><span class="Bold">)</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Effect </span><span class="Bold">on </span><span class="Bold">rifabutin</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Effect </span><span class="Bold">on </span><span class="Bold">coadministered </span><span class="Bold">drug</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Recommendation</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">ANTIVIRALS </span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Amprenavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1200 mg BID x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy male subjects (6)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 193%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 119%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 50%. Monitor closely for adverse reactions.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Delavirdine <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">400 mg TID<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (7)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 230%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 128%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 80%, ↓ Cmax by 75%,<br>↓ C<span class="Sub">m</span><span class="Sub">i</span><span class="Sub">n</span> by 17%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">CONTRAINDICATED</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Didanosine <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">167 or 250 mg BID x 12 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 or 600 mg QD x 1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (11)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Fosamprenavir/ ritonavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">700 mg BID plus ritonavir 100 mg BID x 2 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg every other day x 2 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (15)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔ AUC<span class="Sup">a</span><span class="Sup"> </span>↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 15%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 35%<span class="Sup">b</span>,<br>↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 36%, ↑ C<span class="Sub">m</span><span class="Sub">i</span><span class="Sub">n</span> by 36%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with fosamprenavir/ritonavir combination.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Indinavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">800 mg TID x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (10)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 173%, ↑ Cmax by 134%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 34%, ↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 25%, ↓ C<span class="Sub">m</span><span class="Sub">i</span><span class="Sub">n</span> by 39%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by 50%, and increase indinavir dose from 800 mg to 1000 mg TID.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Lopinavir/<br>ritonavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">400/100 mg BID x 20 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg QD x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (14)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 203%<span class="Sup">c</span><br>↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span><span class="Sub"> </span>by 112%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Saquinavir/ ritonavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1000/100 mg BID x 14 or 22 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg every 3 days X 21 to 22 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 53% <span class="Sup">d</span> ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 88% (n=11)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 13%, ↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 15%, (n=19)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with saquinavir/ritonavir combination. Monitor closely for adverse reactions.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Ritonavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">500 mg BID x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg QD x 16 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (5)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 300%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 150%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Tipranavir/ ritonavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">500/200 BID X 15 doses<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg single dose<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (20)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 190%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 70%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with tipranavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nelfinavir <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1250 mg BID x 7 to 8 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150 mg QD x 8 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (11)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 83%,<span class="Sup">e</span> ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 19%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Reduce rifabutin dose by 50% (to 150 mg QD) and increase the nelfinavir dose to 1250 mg BID<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Zidovudine <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">100 or 200 mg q4h<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 or 450 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (16)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 32%, ↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 48%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Because zidovudine levels remained within the therapeutic range during coadministration of rifabutin, dosage adjustments are not necessary.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top">
<span class="Bold">ANTIFUNGALS </span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Fluconazole <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">200 mg QD x 2 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD x 2 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (12)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 82%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 88%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Monitor for rifabutin associated adverse events. Reduce rifabutin dose or suspend rifabutin use if toxicity is suspected.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Posaconazole <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">200 mg QD x 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD x 17 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (8)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 72%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 31%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 49%, ↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 43%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of posaconazole efficacy.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Itraconazole <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">200 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-Infected patients (6)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑<span class="Sup">f</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 70%, ↓ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 75%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of itraconazole efficacy. In a separate study, one case of uveitis was associated with increased serum rifabutin levels following coadministration of rifabutin (300 mg QD) with itraconazole (600 to 900 mg QD).<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Voriconazole <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">400 mg BID x 7 days (maintenance dose)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD x 7 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy male subjects (12)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 331%, ↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by 195%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by ~100%,<br>↑ C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> by ~100%<span class="Sup">g</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">CONTRAINDICATED</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top">
<span class="Bold">ANTI</span><span class="Bold">-</span><span class="Bold">PCP </span><span class="Bold">(</span><span class="Bold">Pneumocystis </span><span class="Bold">carinii </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span><span class="Bold">) </span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Dapsone <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (16)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 27 to 40%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Sulfamethoxazole-Trimethoprim <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">800/160 mg<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (12)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 15 to 20%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7" valign="top">
<span class="Bold">ANTI</span><span class="Bold">-</span><span class="Bold">MAC </span><span class="Bold">(</span><span class="Bold">Mycobacterium </span><span class="Bold">avium </span><span class="Bold">intracellulare </span><span class="Bold">complex</span><span class="Bold">) </span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Azithromycin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">500 mg QD x 1 day, then 250 mg QD x 9 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (6)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Clarithromycin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">500 mg BID<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (12)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↑ AUC by 75%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↓ AUC by 50%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Monitor for rifabutin associated adverse events. Reduce dose or suspend use of rifabutin if toxicity is suspected. Alternative treatment for clarithromycin should be considered when treating patients receiving rifabutin<br>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7" valign="top">
<span class="Bold">ANTI</span><span class="Bold">-</span><span class="Bold">TB </span><span class="Bold">(</span><span class="Bold"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span><span class="Bold">) </span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Ethambutol <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1200 mg<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD X 7 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (10)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Isoniazid <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD X 7 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (6)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7" valign="top">
<span class="Bold">OTHER </span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Methadone <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20 to 100 mg QD<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD X 13 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">HIV-infected patients (24)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Ethinylestradiol (EE)/ Norethindrone (NE) <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35 mg EE / 1 mg NE X 21 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg QD X 10 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy female subjects (22)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">EE: ↓ AUC by 35%,<br>↓ Cmax by 20% NE: ↓ AUC by 46%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Patients should be advised to use additional or alternative methods of contraception.<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Theophylline <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5 mg/kg<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300 mg X 14 days<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Healthy subjects (11)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">↔<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
</tbody>
</table>
<p><a name="ID71"></a><span class="Bold"><span class="Italics">Other drugs</span></span></p>
<p>The structurally similar drug, rifampin, is known to reduce the plasma concentrations of a number of other drugs (see prescribing information for rifampin). Although a weaker enzyme inducer than rifampin, rifabutin may be expected to have some effect on those drugs as well.</p>
</div>
<div class="Section">
<a name="ID40"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID41"></a>Long-term carcinogenicity studies were conducted with rifabutin in mice and in rats. Rifabutin was not carcinogenic in mice at doses up to 180 mg/kg/day, or approximately 36 times the recommended human daily dose. Rifabutin was not carcinogenic in the rat at doses up to 60 mg/kg/day, about 12 times the recommended human dose.</p>
<p>Rifabutin was not mutagenic in the bacterial mutation assay (Ames Test) using both rifabutin-susceptible and resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Rifabutin was not mutagenic in<span class="Italics"> Schizosaccharomyces pombe P<span class="Sub">1</span> </span>and was not genotoxic in V-79 Chinese hamster cells, human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro</span>, or mouse bone marrow cells <span class="Italics">in vivo</span>.</p>
<p>Fertility was impaired in male rats given 160 mg/kg (32 times the recommended human daily dose). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID42"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy
</h2>
<p class="First"><a name="ID43"></a><span class="Bold"><span class="Italics">Pregnancy Category B</span></span></p>
<p>Rifabutin should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant or breastfeeding women. </p>
<p>Reproduction studies have been carried out in rats and rabbits given rifabutin using dose levels up to 200 mg/kg (about 6 to 13 times the recommended human daily dose based on body surface area comparisons). No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in either species. In rats, given 200 mg/kg/day, (about 6 times the recommended human daily dose based on body surface area comparisons), there was a decrease in fetal viability. In rats, at 40 mg/kg/day (approximately equivalent to the recommended human daily dose based on body surface area comparisons), rifabutin caused an increase in fetal skeletal variants. In rabbits, at 80 mg/kg/day (about 5 times the recommended human daily dose based on body surface area comparisons), rifabutin caused maternotoxicity and increase in fetal skeletal anomalies. Because animal reproduction studies are not always predictive of human response, rifabutin should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID44"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First"><a name="ID45"></a>It is not known whether rifabutin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID46"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First"><a name="ID47"></a>Safety and effectiveness of rifabutin for prophylaxis of MAC in children have not been established. Limited safety data are available from treatment use in 22 HIV-positive children with MAC who received rifabutin in combination with at least two other antimycobacterials for periods from 1 to 183 weeks. Mean doses (mg/kg) for these children were: 18.5 (range 15.0 to 25.0) for infants 1 year of age, 8.6 (range 4.4 to 18.8) for children 2 to 10 years of age, and 4.0 (range 2.8 to 5.4) for adolescents 14 to 16 years of age. There is no evidence that doses greater than 5 mg/kg daily are useful. Adverse experiences were similar to those observed in the adult population, and included <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In addition, <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span> have been observed in some patients during routine ophthalmologic surveillance of HIV-positive pediatric patients receiving rifabutin as part of a multiple-drug regimen for MAC prophylaxis. These are tiny, almost transparent, asymptomatic peripheral and central <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span> which do not impair vision. Doses of rifabutin may be administered mixed with foods such as applesauce.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID48"></a><a name="section-8.8"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First"><a name="ID49"></a>Clinical studies of rifabutin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">(see <a href="#ID5">CLINICAL PHARMACOLOGY</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID50"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="ID51"></a><span class="Bold">Adverse Reactions from Clinical Trials </span></p>
<p>Rifabutin capsules were generally well tolerated in the controlled clinical trials. Discontinuation of therapy due to an adverse event was required in 16% of patients receiving rifabutin, compared to 8% of patients receiving placebo in these trials. Primary reasons for discontinuation of rifabutin were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (4% of treated patients), gastrointestinal intolerance (3%), and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (2%).</p>
<p>The following table enumerates adverse experiences that occurred at a frequency of 1% or greater, among the patients treated with rifabutin in studies 023 and 027.</p>
<a name="ID52"></a><table width="100%">
<col width="44%">
<col width="28%">
<col width="28%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Table </span><span class="Bold">3</span><span class="Bold">: </span><span class="Bold">Clinical </span><span class="Bold">Adverse </span><span class="Bold">Experiences </span><span class="Bold">Reported </span><span class="Bold">in </span><span class="Bold">≥ </span><span class="Bold">1</span><span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Patients </span><span class="Bold">Treated </span><span class="Bold">With </span><span class="Bold">Rifabutin</span><span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Adverse </span><span class="Bold">event</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Rifabutin</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">566</span><span class="Bold">) </span><span class="Bold">%</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Placebo</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">580</span><span class="Bold">) </span><span class="Bold">%</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="justify" valign="top">
<span class="Bold">Body </span><span class="Bold">as </span><span class="Bold">a </span><span class="Bold">whole</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">Abdominal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">4<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">Chest <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Blood </span><span class="Bold">and </span><span class="Bold">lymphatic </span><span class="Bold">system</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leucopenia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Digestive </span><span class="Bold">system</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">Dyspepsia <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">Eructation</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">6<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">Nausea and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Musculoskeletal </span><span class="Bold">system</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Nervous </span><span class="Bold">system</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Skin </span><span class="Bold">and </span><span class="Bold">appendages</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">11<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Special </span><span class="Bold">senses</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">Taste perversion<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Urogenital </span><span class="Bold">system</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top">Discolored urine<br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">30<br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">6<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID53"></a><span class="Bold">Clinical Adverse Events Reported In &lt;1% of Patients Who Received Rifabutin</span></p>
<p>Considering data from the 023 and 027 pivotal trials, and from other clinical studies, rifabutin appears to be a likely cause of the following adverse events which occurred in less than 1% of treated patients: flu-like syndrome, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>The following adverse events have occurred in more than one patient receiving rifabutin, but an etiologic role has not been established: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and non-specific T wave changes on electrocardiogram.</p>
<p>When rifabutin was administered at doses from 1050 mg/day to 2400 mg/day, generalized <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> were reported. These adverse experiences abated when rifabutin was discontinued.</p>
<p>Mild to severe, reversible <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> has been reported less frequently when rifabutin is used at 300 mg as monotherapy in MAC prophylaxis versus rifabutin in combination with clarithromycin for MAC treatment <span class="Italics">(see also <a href="#ID31">WARNINGS</a>). </span></p>
<p><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> has been infrequently reported when rifabutin is used at 300 mg/day as montherapy in MAC prophylaxis of HIV-infected persons, even with the concomitant use of fluconazole and/or macrolide antibacterials. However, if higher doses of rifabutin are administered in combination with these agents, the incidence of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> is higher. FDA proposes moving this paragraph from below with some revisions. </p>
<p>Patients who developed <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> had mild to severe symptoms that resolved after treatment with corticosteroids and/or mydriatic eye drops; in some severe cases, however, resolution of symptoms occurred after several weeks. </p>
<p>When <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> occurs, temporary discontinuance of rifabutin and ophthalmologic evaluation are recommended. In most mild cases, rifabutin may be restarted; however, if signs or symptoms recur, use of rifabutin should be discontinued (Morbidity and Mortality Weekly Report, September 9, 1994). </p>
<p><span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">Corneal deposits</span> have been reported during routine ophthalmologic surveillance of some HIV-positive pediatric patients receiving rifabutin as part of a multiple drug regimen for MAC prophylaxis. The deposits are tiny, almost transparent, asymptomatic peripheral and central <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span>, and do not impair vision.</p>
<p>The following table enumerates the changes in laboratory values that were considered as laboratory abnormalities in Studies 023 and 027. </p>
<a name="ID54"></a><table width="100%">
<col width="50%">
<col width="26%">
<col width="24%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote">Includes grades 3 or 4 toxicities as specified:<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">1</span> All values &gt;450 U/L<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">2</span> All values &gt;150 U/L<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">3</span> All hemoglobin values &lt; 8.0 g/dL<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">4</span> All WBC values &lt; 1,500/mm³<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">5</span> All ANC values &lt; 750/mm³<br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">6</span> All platelet count values &lt; 50,000/mm³<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Table </span><span class="Bold">4</span><span class="Bold">: </span><span class="Bold">Percentage </span><span class="Bold">of </span><span class="Bold">Patients </span><span class="Bold">With </span><span class="Bold">Laboratory </span><span class="Bold">Abnormalities</span><span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Laboratory </span><span class="Bold">abnormalities</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Rifabutin</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">566</span><span class="Bold">) </span><span class="Bold">%</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">580</span><span class="Bold">) </span><span class="Bold">%</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="justify" valign="top">
<span class="Bold">Chemistry</span><br>
</td>
<td class="Lrule Rrule Toprule" align="justify" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="justify" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     Increased alkaline phosphatase<span class="Sup">1</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     Increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span><span class="Sup">2</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">7<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">12<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     Increased SGPT<span class="Sup">2</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">9<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">11<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">
<span class="Bold">Hematology</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><span class="Sup">3</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">6<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span><span class="Sup">4</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top">17<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">16<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="justify" valign="top">     Neutropenia <span class="Sup">5</span>
</td>
<td class="Lrule Rrule" align="center" valign="top">25<br>
</td>
<td class="Lrule Rrule" align="center" valign="top">20<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top">     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span><span class="Sup">6</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">4<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID55"></a>The incidence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients treated with rifabutin was significantly greater than in patients treated with placebo (p = 0.03). Although <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was not significantly more common among patients treated with rifabutin in these trials, rifabutin has been clearly linked to <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in rare cases. One patient in Study 023 developed <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>, which was attributed to rifabutin. </p>
<p><span class="Bold">Adverse Reactions from Post-Marketing Experience </span></p>
<p>Adverse reactions identified through post-marketing surveillance by system organ class (SOC) are listed below: </p>
<p><span class="Bold"><span class="Italics">Blood and lymphatic system disorders</span></span></p>
<p>White blood cell disorders (including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, white blood cell count decreased, neutrophil count decreased), platelet count decreased. </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></span></p>
<p><span class="Italics">Clostridium difficile </span><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>/ <span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> might occur, as has been seen with other antibacterials.</p>
<p>A limited number of <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span> have been reported.  </p>
<p><span class="Bold"><span class="Italics">Rifamycin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to rifamycins have been reported including flu-like symptoms, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span>.</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID56"></a><a name="section-9.1"></a><p></p>
<p class="First"><a name="ID57"></a><span class="Bold">ANIMAL TOXICOLOGY</span></p>
<p>Liver abnormalities (increased bilirubin and liver weight) occurred in mice, rats and monkeys at doses (respectively) 0.5, 1 and 3-times the recommended human daily dose based on body surface area comparisons). <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> occurred in baboons at doses 2 times the recommended human dose based on body surface area comparisons and in rats at doses 6 times the recommended human daily dose based on body surface area comparisons.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID58"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="ID59"></a>No information is available on accidental overdosage in humans.</p>
<div class="Section">
<a name="ID60"></a><a name="section-10.1"></a><p></p>
<h2>Treatment</h2>
<p class="First"><a name="ID61"></a>While there is no experience in the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with rifabutin capsules, clinical experience with rifamycins suggests that gastric lavage to evacuate gastric contents (within a few hours of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>), followed by instillation of an activated charcoal slurry into the stomach, may help absorb any remaining drug from the gastrointestinal tract.</p>
<p>Rifabutin is 85% protein bound and distributed extensively into tissues (Vss:8 to 9 L/kg). It is not primarily excreted via the urinary route (less than 10% as unchanged drug); therefore, neither hemodialysis nor forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is expected to enhance the systemic elimination of unchanged rifabutin from the body in a patient with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of rifabutin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID62"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="ID63"></a>It is recommended that rifabutin capsules USP be administered at a dose of 300 mg once daily. For those patients with propensity to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or other <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>, administration of rifabutin at doses of 150 mg twice daily taken with food may be useful. </p>
<p>For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min), consider reducing the dose of rifabutin by 50%, if toxicity is suspected. No dosage adjustment is required for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Reduction of the dose of rifabutin may also be needed for patients receiving concomitant treatment with certain other drugs <span class="Italics">(see <a href="#ID33">PRECAUTIONS</a>-<a href="#ID38">Drug Interactions</a>).</span></p>
<p>Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not known.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID64"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="ID65"></a>Rifabutin Capsules USP are supplied as size '0' capsules having opaque red-brown cap imprinted with 'LU' in white ink and opaque red-brown body imprinted with 'R01' in white ink, containing red-violet granular powder equivalent to 150 mg of rifabutin USP.</p>
<p>Rifabutin Capsules USP are available as follows: </p>
<p>Bottles of 60 capsules - NDC 68180-285-07</p>
<p>Bottles of 100 capsules - NDC 68180-285-01</p>
<p>Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. </p>
<p>Keep tightly closed and dispense in a tight container as defined in the USP. Protect from light and from excessive heat.</p>
<p>Manufactured for:</p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.</span></p>
<p>Baltimore, Maryland 21202</p>
<p>United States</p>
<p> </p>
<p>Manufactured by: </p>
<p><span class="Bold">Lupin Limited</span></p>
<p>Aurangabad 431 210</p>
<p>INDIA</p>
<p>Revised: October 2015                                                                                      ID#: 242333</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID66"></a><a name="section-13"></a><p></p>
<p class="First"><a name="ID67"></a>Rifabutin Capsules USP, 150 mg</p>
<p>NDC 68180-285-01</p>
<p>A Bottle Label containing 100 capsules</p>
<div class="Figure"><img alt="NDC 38180-285-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4be9cc3f-0016-4426-a700-574b45ce245b&amp;name=rifabutincaps-figure-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIFABUTIN 		
					</strong><br><span class="contentTableReg">rifabutin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68180-285</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIFABUTIN</strong> (RIFABUTIN) </td>
<td class="formItem">RIFABUTIN</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Opaque red-brown cap) , BROWN (Opaque red-brown body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LU;R01</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68180-285-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68180-285-07</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090033</td>
<td class="formItem">03/26/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lupin Pharmaceuticals, Inc.
							(089153071)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>LUPIN LIMITED (675923163)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LUPIN LIMITED</td>
<td class="formItem"></td>
<td class="formItem">862272739</td>
<td class="formItem">manufacture(68180-285)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9df90e3e-1e87-45d5-9fa9-74d44f371128</div>
<div>Set id: 4be9cc3f-0016-4426-a700-574b45ce245b</div>
<div>Version: 3</div>
<div>Effective Time: 20151001</div>
</div>
</div> <div class="DistributorName">Lupin Pharmaceuticals, Inc.</div></p>
</body></html>
